3 New Reasons to Sell Viatris Stock Right Now
With shares of the generic medication manufacturer Viatris (NASDAQ: VTRS) collapsing by around 28% in the last five days after its weak fourth-quarter earnings report, I don't blame anyone who's looking for the door. For a company whose appeal to investors relies on the slow march of small gains compounding over time, such turbulence is confidence-shaking, to say the least.
What's more, there's reason to believe that things won't be looking up for at least another year. It's still possible that the stock could be worth holding in the long term, but for now, shareholders aren't experiencing any deficit of reasons to sell, so let's look at the three most important ones.
Image source: Getty Images.
Source Fool.com
